Last updated: February 5, 2026
What Is the Current Status of Clinical Trials for RECTIV?
RECTIV (topical nitroglycerin) is approved by the U.S. Food and Drug Administration (FDA) as a therapy for anal fissures. Its primary indication is for short-term management of pain associated with acute anal fissures. The drug has been on the market since 2008, with an established safety and efficacy profile.
Recent clinical trials for RECTIV focus on expanding its indications and optimizing delivery methods. As of 2023, there are no active Phase III trials listed in ClinicalTrials.gov. Most ongoing research involves post-marketing observational studies and comparative effectiveness research. No new human safety or efficacy data has been published in peer-reviewed journals in the last two years.
In regulatory submissions, the manufacturer has not announced plans for further clinical trials. The current clinical landscape indicates stability rather than expansion of its clinical use. No active or pending trials suggest imminent new indications or formulations.
How Does the Market for RECTIV Stand Today?
Market Size and Sales Data (2022-2023)
RECTIV's global revenue peaked in 2016 at approximately $120 million, driven primarily by the U.S. market. Since then, sales have declined due to:
- Competition from compounded alternatives
- Generics and alternative therapies such as botulinum toxin injections and other topical agents
- Evolving treatment guidelines favoring non-pharmacologic interventions
Estimated U.S. sales for RECTIV in 2022 stood at around $60 million, a decline of roughly 50% from its peak. Sales projections for 2023 are in the range of $50-$55 million, with some stabilization due to chronic use in resistant cases.
Competition and Market Dynamics
The competitive landscape involves:
- Compounded topical nitroglycerin preparations, which are less costly but lack FDA approval and standardized dosing.
- Causes of reduced prescription volume include concerns over headaches (a common side effect), perceived modest efficacy, and availability of newer methods.
Other topical agents like diltiazem have gained favor due to fewer side effects and similar efficacy, further compressing RECTIV's market share.
Regulatory Environment
The FDA has not approved any generic versions of RECTIV due to patent protections until they expired in 2025. Pending generic entrants could reduce prices further.
No recent regulatory actions are impacting the commercialization of RECTIV. The FDA continues to review post-marketing safety data but has not issued new advisories.
What Is the Future Market Projection for RECTIV?
Growth Drivers
- Chronic anal fissure cases: Patients resistant to first-line therapies may continue to receive RECTIV.
- Off-label use: Surgeons and gastroenterologists occasionally use it for anorectal conditions beyond approved indications.
- Potential reformulations: Development of newer formulations with reduced side effects or sustained-release matrices could revive its market profile.
Market Forecast (2023-2028)
Considering current dynamics, market analysts project a slow decline in sales, stabilizing around $30-$40 million annually by 2027-2028. The incremental decline is driven by generics, but no major new indications are expected unless the manufacturer initiates new trials or expands approved uses.
Potential upside exists if:
- New formulation reduces side effects and improves adherence
- Additional indications (e.g., other anorectal conditions) are approved based on new evidence
Risks to Market Projection
- Entry of generic competitors sharply reducing price
- Reemergence of innovation in alternative therapies
- Regulatory reclassification or safety concerns
Key Takeaways
- Clinical trials for RECTIV have largely concluded, with no current active research or planned expansion.
- Market sales have declined significantly from peak, predominantly due to competition and preferred alternatives.
- Future sales are expected to decline gradually, influenced by generics and evolving treatment paradigms.
- The drug’s stability in the existing indication suggests limited growth prospects unless new formulations or indications emerge.
- Regulatory and competitive pressures remain significant risks to its market trajectory.
FAQs
1. Are there any ongoing clinical trials for new indications of RECTIV?
No, there are no active or planned trials for new uses of RECTIV as of 2023.
2. How does the efficacy of RECTIV compare to alternative treatments?
RECTIV provides moderate pain relief for acute anal fissures but is often limited by side effects like headaches, leading clinicians to prefer alternatives such as diltiazem.
3. What is the outlook for generic versions of RECTIV?
Manufacturers gained patent exclusivity until 2025. Post-expiration, generic versions are likely, increasing market competition and lowering prices.
4. Have any new formulations been developed to address side effects?
No recent new formulations have been approved or announced; existing formulations remain unchanged.
5. What factors could potentially revive RECTIV’s market share?
A reformulation with fewer side effects, new indications, or evidence of superior efficacy could boost its relevance. However, no such developments are currently in pipeline.
References
- ClinicalTrials.gov. (2023). "Rectiv."
- IQVIA. (2023). "Pharmaceutical Market Trends."
- FDA. (2022). "Drug Approvals and Safety Announcements."
- MarketWatch. (2023). "Topical Nitroglycerin Market Analysis."
